Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 603 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ph+ ALL Clear all
Completed Phase 2 Interventional Results available

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

NCT00343044
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Topotecan, Bevacizumab
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient

NCT01528384
View directory record Official record
Conditions
Argininosuccinate Synthetase Deficient
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
4 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated No phase listed Observational

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00008216
View directory record Official record
Conditions
Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Peripheral Blood Stem Cell Transplantation
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Sep 11, 2026, 4:37 AM EDT
Withdrawn Phase 1 Interventional

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

NCT03414450
View directory record Official record
Conditions
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Ph- Acute Lymphoblastic Leukemia (Ph-ALL), Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+), Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)
Interventions
ETC-1907206, dasatinib
Drug
Lead sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Government
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Bethesda, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 11, 2026, 4:37 AM EDT
Recruiting Phase 2 Interventional

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT07333183
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
inhaled mosliciguat, Dry Powder Inhaler
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Results available

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490
View directory record Official record
Conditions
Advanced Melanoma, Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Lutherville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 4 Interventional Results available

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

NCT02228382
View directory record Official record
Conditions
Previously Treated PH + CML
Interventions
Bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Deerfield Beach, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Assessment of Esophageal Epithelium Integrity With Mucosal Impedance

NCT02318862
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Non-erosive Reflux Disease (NERD)
Interventions
Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

NCT00313768
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
paclitaxel + carboplatin + bevacizumab, carboplatin + paclitaxel + bevacizumab + PF-3512676
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
29
States / cities
Bessemer, Alabama • Birmingham, Alabama • Mobile, Alabama + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2009 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Phase 1 Interventional

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

NCT02494882
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Ruxolitinib, Dasatinib, Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Phase 2 Interventional

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04329325
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive
Interventions
Blinatumomab, dasatinib, dexamethasone, methotrexate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Withdrawn Phase 1 Interventional

Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

NCT02647190
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Newly Diagnosed Philadelphia Chromosome Negative, Aged 60 Years or Older
Interventions
Erwinia Chrysanthemi asparaginase
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

NCT00678652
View directory record Official record
Conditions
Meningococcal Infection, Group B
Interventions
10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 11, 2026, 4:37 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655
View directory record Official record
Conditions
Pulmonary Hypertension Due to Lung Disease (Disorder)
Interventions
L606, Placebo
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

NCT00612638
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temodar, O6-BG, and Irinotecan
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Early Phase 1 Interventional

A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)

NCT04193046
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Blood Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

NCT02651727
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine, Part A- VS-4718, nab-paclitaxel, gemcitabine
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
St Louis, Missouri • Gettysburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
TAR-200, Mitomycin C, Gemcitabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Not yet recruiting Phase 2 Interventional

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

NCT07178912
View directory record Official record
Conditions
Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Interventions
Blinatumomab, olverembatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated No phase listed Observational

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

NCT01073436
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Discontinuation of therapy
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Sep 11, 2026, 4:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Horton & Maizy Pilot Study for Resistant to Starch

NCT01338571
View directory record Official record
Conditions
pH, Weight Gain
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
5 Years to 15 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

NCT05027594
View directory record Official record
Conditions
Multiple Myeloma
Interventions
NMS-03597812, NMS-03597812 + dexamethasone
Drug
Lead sponsor
Nerviano Medical Sciences
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated No phase listed Observational

Comparison of RightSpot pH Indicator & RightLevel pH Detector With X-Ray Verification for FT or G-Tube Placement

NCT01825564
View directory record Official record
Conditions
Gastrostomy
Interventions
Not listed
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Ph I SU011248 + Irinotecan in Treatment of Pts w MG

NCT00611728
View directory record Official record
Conditions
Glioblastoma
Interventions
SU011248 & Irinotecan
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 11, 2026, 4:37 AM EDT